Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm

Ulrickson, Matthew L.; Puri, Akshjot; Lindstrom, Sarah L.; Cassaday, Ryan D.; Padova, Nicolas De; Becker, Pamela S.

doi:10.1002/ajh.24696

Cited by 14 publications

(8 citation statements)

References 5 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 Elderly patients are treated with lower intensity chemotherapy regimens like pralatrexate, bendamustine, or gemcitabine/docetaxel combinations or hypomethylating agents like 5-azacytidine which demonstrated transient responses. [25][26][27][28] Novel Agents in Blastic Plasmacytoid Dendritic Cell Neoplasm Literature reveals that low-intensity treatments have unsatisfactory results, whereas intensive therapies lead to toxicity. Thus, there was a need for the use of novel targeted agents for the treatment of BPDCN.…”

Section: Discussionmentioning

confidence: 99%

“…29 Promising result with CR rate of 79% (first line) and 31% CR rate, a phase-II study with SL401 has been shown and reported at the 2017 ASH -American Society of Hematology for relapsed/refractory patients. [27][28][29] Phase-I trials are ongoing with other immunotherapies targeting CD123 which includes immunoconjugates, chimeric antigen receptor (CAR)-T-cells, and bispecific antibodies. 28 Venetoclax (BCL-2 inhibitor) has demonstrated high single-agent activity in myeloid malignancies.…”

Section: Discussionmentioning

confidence: 99%

“…Bromodomain and extra terminal domain inhibitors (BETs) are being studied in preclinical tests. 27,28 SCT with myeloablative or reduced intensity regimen have shown improved survival in younger and selected elderly patients. The clinical course and response to the treatment is best when the procedure is performed after first CR.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rare Case Report with Literature Review

Oza

Rathnam

Gujral

et al. 2021

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic neoplasm for which there are no effective therapies. We present a 70-year-old male patient with multiple reddish painless, nonpruritic, and nonpedunculated nodules over the trunk, forearm, and thighs for a duration of 3 months. The nodules measured 0.5 to 2 cm in diameter. The peripheral smear findings were within normal limits. Excision biopsy was performed. Histomorphology and immunohistochemistry (CD123, CD 56, CD4, HLA-DR, CD43, and CD68) confirmed the diagnosis of BPDCN. Findings of marrow aspiration, biopsy and imaging studies were within normal limits. Patient demonstrated a good response with complete disappearance of all nodules by initial 2 weeks of therapy with a modified Berlin–Frankfurt–Munster (BFM) acute lymphoblastic leukemia (ALL) protocol and has completed 8 doses (LSAP [lincosamides, streptogramins A and pleuromutilins chemotherapy], 5,000 units/m2). The patient tolerated protocol extremely well.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rare Case Report with Literature Review

Oza

Rathnam

Gujral

et al. 2021

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

“…Gemcitabine, a well-known nucleoside analog, was found to be efficient in an 80-year-old patient with BPDCN. 8 Ulrickson et al 9 reported three patients with relapsed BPDCN who received the gemcitabine/docetaxel regimen (gemcitabine 800 mg/m 2 days 1 and 8 and docetaxel 75 mg/m 2 day 8 every 3 weeks); the median overall survival (OS) was 13.3 months (range 8–17 months) with one patient remaining alive and in remission 15 months after treatment. Bétrian et al 10 reported five patients treated with bendamustine hydrochloride, a well-tolerated bifunctional drug acting as an alkylating and antimetabolite agent.…”

Section: Discussionmentioning

confidence: 99%

Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature review

Wang¹,

Guo²,

Wan³

et al. 2018

TCRM

View full text Add to dashboard Cite

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematopoietic malignancy mainly affecting elderly patients. It is highly responsive to chemotherapy, but the median event-free survival is very short and has a high rate of relapse even after performing allogeneic stem cell transplantation; thus, the discovery of novel agents for the treatment of BPDCN is urgent. Chidamide is a new oral isotype-selective histone deacetylase inhibitor (HDACi). It is proved to exert a well-characterized anticancer property in a wide range of hematological malignancies, especially lymphoma. Here, we report a 41-year-old man who used oral chidamide 30 mg twice per week for maintenance therapy after receiving complete remission. For the first time in this field, we had explored the efficiency of chidamide in the treatment of BPDCN and tried to give more choices to the therapy of this disease.

show abstract

“…For elderly patients, lower intensity treatments can be explored. Lower intensity chemotherapy regimens demonstrated some efficacy in BPDCN, such as single agent pralatrexate, bendamustine, or gemcitabine/docetaxel combinations [100,101,102,103]. However, despite the promising results, these studies were performed on a small number of patients, and which ought to be validated in larger future studies.…”

Section: Therapy Of Blastic Plasmacytoid Dendritic Neoplasmmentioning

confidence: 99%

Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects

Sapienza

Pileri

Derenzini

et al. 2019

Cancers

View full text Add to dashboard Cite

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare tumour, which usually affects elderly males and presents in the skin with frequent involvement of the bone-marrow, peripheral blood and lymph nodes. It has a dismal prognosis, with most patients dying within one year when treated by conventional chemotherapies. The diagnosis is challenging, since neoplastic cells can resemble lymphoblasts or small immunoblasts, and require the use of a large panel of antibodies, including those against CD4, CD56, CD123, CD303, TCL1, and TCF4. The morphologic and in part phenotypic ambiguity explains the uncertainties as to the histogenesis of the neoplasm that led to the use of various denominations. Recently, a series of molecular studies based on karyotyping, gene expression profiling, and next generation sequencing, have largely unveiled the pathobiology of the tumour and proposed the potentially beneficial use of new drugs. The latter include SL-401, anti-CD123 immunotherapies, venetoclax, BET-inhibitors, and demethylating agents. The epidemiologic, clinical, diagnostic, molecular, and therapeutic features of BPDCN are thoroughly revised in order to contribute to an up-to-date approach to this tumour that has remained an orphan disease for too long.

show abstract

Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm

Cited by 14 publications

References 5 publications

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rare Case Report with Literature Review

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rare Case Report with Literature Review

Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature review

Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects

Contact Info

Product

Resources

About